ChemDiv

ChemDiv has become a globally recognized leader in the field of discovery chemistry, possessing the largest, most diverse, and most pharmacologically relevant commercial product portfolio in the industry, which includes more than 1.5 million individually crafted lead-like drug-like small molecules. ChemDiv conducts preclinical discovery chemistry and biology for an international portfolio of companies across the entire range of targets for small molecule and biotech drugs, aiding in drug development and clinical trials. The company operates multiple R&D subsidiaries in Russia, Ukraine, and China, with business conducted worldwide.Representative examples of ChemDiv's services include synthetic chemistry, structural biology and structure-based drug discovery, molecular modeling, medicinal chemistry, analytical/bioanalytical platforms, ADME/toxicology, DMPK, and various in vivo efficacy/toxicity models.